IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

~ All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM). ~ Company-sponsored Phase 2 multi-center clinical trial of autologous INB-400 gamma-delta T cells in newly diagnosed GBM patients to start enrollment by Q3 2023. ~ Submission of Investigational New Drug Application (IND) for the Phase 1b trial of INB-410, a genetically modified allogeneic gamma-delta T cell therapy in relapsed and newly diagnosed GBM anticipated in 2H 2023. ~ Announcement of a new solid tumor indication with relevant data at a scientific conference in 1H 2023.